Hematology/Medical Oncology
Joined January 2011
- Tweets1.9K
- Following810
- Followers845
- Likes8.3K
Patrick Reville, MD, MPH retweeted
UT MD Anderson researchers discovered that immunosuppressed patients with non-melanoma skin cancer are not missing the key cancer-fighting immune cells, but those cells have lost the ability to communicate effectively.
spr.ly/6016B18WwK @moranamit2 @raikunal @PriyathersiniN #EndCancer
Patrick Reville, MD, MPH retweeted
🧵1/
Thrilled to share our lab’s first paper, just out in @BloodCancerDisc led by the talented @Cuijuan3
We uncovered an isoform-specific RUNX1C–BTG2 axis that drives chemoresistance in AML.
👉 aacrjournals.org/bloodcancer…
Patrick Reville, MD, MPH retweeted
Online First: An isoform-specific RUNX1C–BTG2 axis governs AML quiescence and chemoresistance. brnw.ch/21wU1As
Patrick Reville, MD, MPH retweeted
Happy to share our newest work out today in BCD evaluating disease classification and prognosis in the “world of myeloid malignancies”! Wonderful collaboration with @sanamloghavi @PapaemmanuilLab @Elsa2Bernard and colleagues.
Online First: Multi-Modal and Data-Driven Assessment of Myeloid Neoplasms Refines Classification Across Disease States brnw.ch/21wTSQI
Patrick Reville, MD, MPH retweeted
Oncostatin M receptor is a single marker with strong predictive power of patient outcome, induction therapy response, and early mortality. ow.ly/a8Jq50WcXTJ #myeloidneoplasia
Patrick Reville, MD, MPH retweeted
Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy–Ineligible Patients With Isocitrate Dehydrogenase–Mutated AML. Co-authored by @JenMarvinPeek.
Full article. brnw.ch/21wTx9F
Patrick Reville, MD, MPH retweeted
Our #Opal bone marrow image is featured on the new @BloodPortfolio cover, highlighting the discovery of OSMR as a novel #AML biomarker. This work was led by @HusseinAbbasLab, @patrickreville, @BofeiWang3 and @JenMarvinPeek at @MDAndersonNews. Learn more: bit.ly/4d5MdC5
Patrick Reville, MD, MPH retweeted
🧵1/
T cells have deservedly been in the🔦for #cancer #immunotherapy, but other engineered cell therapies are now📈. What mediates NK cell exhaustion remains an important unanswered❓.
📄Link: nature.com/articles/s41586-0…
I’m so thrilled🥳to share our work out now🚨@Nature identifying🔎CREM as a central intracellular checkpoint🚦in #CARNK cells.
Let me tell you a story...👇🏼
New paper, we used spectral flow cytometry panels to characterize AML and T cells. @HusseinAbbasLab
Comprehensive Profiling of AML and T Cell States Across Disease Stages in Acute Myeloid Leukemia Using Spectral Flow Cytometry
ashpublications.org/bloodict…
Multimodal spatial proteomic profiling in acute myeloid leukemia
nature.com/articles/s41698-0…
Patrick Reville, MD, MPH retweeted
Our new publication is out today in the OnlineFirst section of @BCD_AACR!
We explored correlations between monocytic AML, genetics, and survival by leveraging a large international clinical cohort of patients with AML treated with HMA+VEN.
aacrjournals.org/bloodcancer…
Patrick Reville, MD, MPH retweeted
MD Anderson researchers recently identified an eight-protein blood signature to help predict outcomes for patients with acute myeloid leukemia.
One protein stood out as a key predictor of survival and early treatment risk. Learn more: brnw.ch/21wRT0h #EndCancer
Patrick Reville, MD, MPH retweeted
➡️ Excited to share the phase 1b/2 clin trial of Aza-Ven-Magro in ND high-risk & R/R AML from @MDAndersonNews led by @Daver_Leukemia, just out in @CCR_AACR
✅ Interesting correlative analysis by @HusseinAbbasLab interrogating mech of Magro resistance in TP53-mut AML
✅Despite neg results from Ph3 ENHANCE trials, this is possibly the first data evaluating mech of resistance to AVM in AML 🏁⏩can help tune anti-CD47 approaches in the future
aacrjournals.org/clincancerr…
New publication, online now @BloodJournal
Blood-Based Proteomic Profiling Identifies OSMR as a Novel Biomarker of AML Outcomes
@BofeiWang3 @JenMarvinPeek @HusseinAbbasLab
ashpublications.org/blood/ar…
Patrick Reville, MD, MPH retweeted
Featured on the new journal cover:
Single-Cell CD4 and CD8 T-Cell Secretome Profiling Reveals Temporal and Niche Differences in Acute Myeloid Leukemia Following Immune Checkpoint Blockade Therapy
brnw.ch/21wQbfm
@HusseinAbbasLab @Daver_Leukemia @patrickreville
Patrick Reville, MD, MPH retweeted
Our Dr. Patrick Reville presented results at #ASH24 of a trial of Atezolizumab combined with Venetoclax and Obinutuzumab as a first-line treatment for patients with chronic lymphocytic leukemia (CLL) that showed a four-year overall survival rate of 94%. @patrickreville #EndCancer
ALT Dr. Patrick Reville presenting
ALT Slide showing overall survival
ALT Side showing patient disposition
Patrick Reville, MD, MPH retweeted
Atezo+VO 1L CLL @patrickreville #ASH24:
- 37 pts, no TP53/del17p, mFU 40 mos
- 4-yr PFS 89%, OS 94%
- 97% BMBx uMRD4, 3 PD events but no subsequent tx req'd
- 3 pts d/c'd d/t irAEs (colitis, hepatitis)
Transcriptomic data attached. Fascinating! #leusm #lymsm
Patrick Reville, MD, MPH retweeted
Consensus Recommendations from the 2024 Lymphoma Research Foundation Workshop on Treatment Selection and Sequencing in CLL or SLL ashpublications.org/bloodadv…
It was awesome to collaborate with great colleagues and friends on this! Thanks @lymphoma for the support. @DebbieMStephens @calliecoombsmd @MCThompsonMD @KrishPatelMD @AdamKittai @andrewlipskymd
Patrick Reville, MD, MPH retweeted
Here’s a closer look at recent #JITC article “Paired single-B-cell transcriptomics & receptor sequencing reveal activation states & clonal signatures that characterize B cell immunity in AML” by @HusseinAbbasLab @PatrickReville @GopiSMohan @Nance_GSN @DapengHao from @MDAndersonNews @HMU_UNI 1/10
Patrick Reville, MD, MPH retweeted
How do BAF (SWI/SNF) mutations drive lymphoma? Back-to-back papers from our group @MDAndersonNews and @LabMelnick lab on SMARCA4 and ARID1A mutations online in @Cancer_Cell today. A brief summary...
sciencedirect.com/science/ar…